NASDAQ: INCY       Incyte Corp
Last Price Today's Change   Day's Range   Trading Volume
83.06   -2.19 (2.57%)  82.765 - 85.69  1,231,384


Avg Volume (4 weeks):1,594,747
4 Weeks Range:81.25 - 96.33
4 Weeks Price Volatility (%):
52 Weeks Range:80.85 - 144.32
52 Weeks Price Volatility (%):
Average Price Target: 120.00
Price Target Upside/Downside: +36.94


No recent Headlines for this stock.

Business Background

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

  Be the first to like this.


1442  6024  511  585 

Top 10 Active Counters
 SPY 258.05-5.62 
 MU 54.21-4.71 
 BAC 29.17-1.38 
 TVIX 10.57+1.05 
 XLF 26.82-0.84 
 GE 13.07-0.28 
 EEM 46.89-0.97 
 QQQ 158.51-4.29 
 UVXY 20.24+1.56 
 GDX 22.12+0.62 
Partners & Brokers